Humanigen Stock Price

0.20 (7.43%)
Volume 450
Bid Price 2.77
Ask Price 2.83
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Humanigen Inc HGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.20 7.43% 2.89 07:00:03
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
23 450 - 2.67 - 29.20
Last Trade Time Type Quantity Stock Price Currency
07:01:05 4 $ 2.80 USD


Draw Mode:

Humanigen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 184.43M 63.82M 42.53M $ 312.00k $ - -2.24 -0.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 108.36k 0.90%

more financials information »

Humanigen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.223.302.672.821,367,714-0.33-10.25%
1 Month3.744.202.673.481,603,498-0.85-22.73%
3 Months6.958.382.674.952,119,817-4.06-58.42%
6 Months15.9618.64732.677.222,163,569-13.07-81.89%
1 Year18.9829.202.6713.072,097,096-16.09-84.77%
3 Years10.8529.202.6713.101,794,605-7.96-73.36%
5 Years10.8529.202.6713.101,794,605-7.96-73.36%

Humanigen Description

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.